The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.